Modality
Cell Therapy
MOA
BCMA ADC
Target
JAK1
Pathway
Complement
DLBCL
Development Pipeline
Preclinical
Sep 2022
→ Oct 2030
PreclinicalCurrent
NCT05363873
1,920 pts·DLBCL
2023-07→2030-10·Not yet recruiting
NCT06308826
2,601 pts·DLBCL
2022-09→2026-02·Terminated
4,521 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-211mo agoInterim· DLBCL
2030-10-224.6y awayInterim· DLBCL
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2026-02-21 · 1mo ago
DLBCL
Interim
2030-10-22 · 4.6y away
DLBCL
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05363873 | Preclinical | DLBCL | Not yet recr... | 1920 | EASI-75 |
| NCT06308826 | Preclinical | DLBCL | Terminated | 2601 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |